New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
09:45 EDTABT, ABT, THOR, THOR, TFX, TFX, SYK, SYK, STJ, STJ, NUVA, NUVA, MDT, MDT, HTWR, HTWR, HSP, HSP, EW, EW, COV, COV, CFN, CFN, BDX, BDX, BSX, BSX, BCR, BCR, BAX, BAX, ZMH, ZMHBarclays' U.S. medical suppplies & devices analysts hold a conference call
U.S. Medical Supplies & Devices Research Team discuss key potential catalysts and top ideas for 2013 on an Analyst/Industry conference call. Relevant covered companies ABT, BAX, BCR, BSX, BDX, CFN, COV, EW, HSP, HTWR, MDT, NUVA, STJ, SYK, TFX, THOR and ZMH will be discussed on the Analyst/Industry conference call to be held January 17 at 10 am.
News For ABT;BAX;BCR;BSX;BDX;CFN;COV;EW;HSP;HTWR;MDT;NUVA;STJ;SYK;TFX;THOR;ZMH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 24, 2015
10:00 EDTSTJOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AMC Networks (AMCX) downgraded to Neutral from Outperform at Macquarie... American Airlines (AAL) downgraded to Market Perform at Cowen... Armstrong World (AWI) downgraded to Hold from Buy at KeyBanc... Basic Energy (BAS) downgraded to Outperform from Strong Buy at Raymond James... CSC (CSC) downgraded at Stifel... Chevron (CVX) downgraded to Perform from Outperform at Oppenheimer... Choice Hotels (CHH) downgraded to Underweight from Equal Weight at Barclays... Eni SpA (E) downgraded to Underperform from Hold at Jefferies... Fifth Street Asset (FSAM) downgraded to Neutral from Outperform at Credit Suisse... HSBC (HSBC) downgraded to Neutral from Buy at UBS... Home Loan Servicing (HLSS) downgraded to Neutral from Overweight at Piper Jaffray... Huntington Ingalls (HII) downgraded to Underperform from Neutral at Credit Suisse... International Paper (IP) downgraded to Hold from Buy at Deutsche Bank... Kayne Anderson (KED) downgraded at Stifel... Landstar System (LSTR) downgraded to Hold from Buy at Deutsche Bank... Multi-Color (LABL) downgraded to Neutral from Long-Term Buy at Hilliard Lyons... Newmont Mining (NEM) downgraded to Neutral from Overweight at HSBC... ONEOK Partners (OKS) downgraded to Underweight from Neutral at JPMorgan... ONEOK (OKE) downgraded to Underweight from Neutral at JPMorgan... Olympic Steel (ZEUS) downgraded to Underperform from Neutral at Credit Suisse... Polypore (PPO) downgraded to Market Perform from Outperform at William Blair... Rosetta Resources (ROSE) downgraded to Equal Weight from Overweight at Stephens... Salix (SLXP) downgraded to Neutral from Buy at UBS... Sprint (S) downgraded to Sell from Neutral at BTIG... St. Jude Medical (STJ) downgraded to Underperform from Outperform at Credit Suisse... Timmins Gold (TGD) downgraded on lack of near-term production catalysts at RBC Capital... Transocean Partners (RIGP) downgraded to Underweight from Equal Weight at Barclays... Vodafone (VOD) downgraded to Underperform from Neutral at BofA/Merrill... Williams Partners (WPZ) downgraded to Neutral from Buy at Citigroup... Williams (WMB) downgraded to Neutral from Buy at Citigroup... Worthington (WOR) downgraded to Neutral from Outperform at Credit Suisse... Zillow Group (Z) downgraded at Macquarie.
07:14 EDTSTJSt. Jude Medical downgraded to Underperform from Outperform at Credit Suisse
Credit Suisse downgraded St. Jude Medical two notches to Underperform based on expectations the Cardiac Rhythm Management segment and shares will under perform peers given competition from Medtronic's (MDT) Quadriplar ICD U.S. launch, Boston Scientific's (BSX) next-gen launch of its subcutaneious ICD, MRI-safe ICD competition in Japan, and the delay in the return of St. Jude's Nanostim to the European market. Price target is $74.
February 23, 2015
09:59 EDTTFXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:08 EDTBAXBaxter announces Illinois headquarters for biopharmaceutical spin-off
Subscribe for More Information
08:40 EDTMDTMedtronic acquires Advanced Uro-Solutions, terms not disclosed
Medtronic announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed.
07:28 EDTHTWRHeartWare recall should not have material impact long-term, says Canaccord
Canaccord does not believe the voluntary recall issued by HeartWare should not have any material impact on its business long-term, as the serious event rate is relatively low. The recall pertains to a previously known issue and is in effect a continuation of its 2013 corrective action, Canaccord said. The firm reiterated its Buy rating and $115 price target on HeartWare shares.
05:45 EDTTFXTeleflex upgraded to Overweight from Equal Weight at Barclays
Subscribe for More Information
February 20, 2015
16:35 EDTHTWRHeartWare issues recall of older HeartWare clinical trial controllers
Subscribe for More Information
15:09 EDTBDXBecton Dickinson management to meet with JPMorgan
Meetings to be held in New York on February 24 and in Atlanta on February 25 hosted by JPMorgan.
14:43 EDTSTJSt. Jude Medical raises quarterly dividend 7%
Subscribe for More Information
12:19 EDTMDTFDA approves closure system to permanently treat varicose veins
Subscribe for More Information
08:27 EDTSYKStryker has a conference call hosted by JPMorgan
Subscribe for More Information
07:08 EDTBSX, BAX, ABTAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
07:02 EDTTFXTeleflex sees FY15 adjusted EPS $6.10-$6.35, consensus $6.26
Sees FY15 revenue up 4%-6% on a constant currency basis. On a GAAP basis, revenues are expected to be flat to down 2% versus the prior year due to the unfavorable impact of foreign currency. Consensus is $1.87B.
07:01 EDTTFXTeleflex reports Q4 adjusted EPS $1.43, consensus $1.38
Subscribe for More Information
February 19, 2015
18:25 EDTBAXPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
16:15 EDTMDTMedtronic SANTE trial data show sustained safety, improvements in QOLIE-31
Subscribe for More Information
11:56 EDTBCRC.R. Bard repoprts CMS approves pass-through payment for Lutonix DCB
Subscribe for More Information
07:12 EDTCFNWharton Health Care Club to hold a conference
Subscribe for More Information
06:17 EDTHSPHospira Inflectra patient registry reports interim results in treatment of IBD
Data have been presented on the use of Hospira's Inflectra, the world's first approved biosimilar monoclonal antibody, or mAb, at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases, or ECCO-ibd, conference. Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade, for inducing and maintaining remission in Crohn's disease, or CD, and ulcerative colitis, or UC. These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease, or IBD. Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment. C-reactive protein, or CRP, a marker of inflammation, was also decreased during induction therapy for UC. Four of the 90 patients showed an allergic reaction to treatment, all of who had previously received anti-TNF medication. The abstract can be found at: P314 Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use